What's Happening?
Jyong Biotech Ltd., a biotechnology company based in Taiwan, has been awarded the Innovation Gold Award in the Pharmaceutical Category at the 2025 Taipei Biotech Awards. The award was given for the development of BOTRESO®, an oral plant-derived investigational new drug aimed at treating benign prostatic hyperplasia and lower urinary tract syndrome. BOTRESO® has completed four Phase III clinical trials in the United States and Taiwan and is the first Taiwan-developed oral botanical drug to receive U.S. FDA Investigational New Drug approval. The award, presented by Taipei City Mayor Wayne Chiang, includes a cash prize of over US$26,000.
Why It's Important?
The recognition of Jyong Biotech's BOTRESO® highlights the growing importance of plant-derived pharmaceuticals in the global healthcare market. This award underscores the company's leadership in botanical drug innovation and its commitment to addressing critical healthcare needs. The successful development and clinical trials of BOTRESO® in the U.S. and Taiwan demonstrate the potential for botanical drugs to offer effective treatments for urinary system diseases, which could lead to increased acceptance and integration of plant-based therapies in mainstream medicine.
What's Next?
Jyong Biotech plans to continue expanding its global presence and delivering innovative botanical drugs to meet healthcare needs worldwide. The company has submitted a New Drug Application to the U.S. FDA, which, if approved, could pave the way for BOTRESO® to enter the U.S. market. This development may encourage further investment in botanical drug research and development, potentially leading to new therapeutic options for patients suffering from urinary system diseases.
Beyond the Headlines
The success of Jyong Biotech's BOTRESO® may influence the pharmaceutical industry to explore more plant-derived drug candidates, potentially shifting the focus towards sustainable and natural drug development. This could lead to a broader acceptance of botanical drugs, impacting regulatory policies and encouraging more research into plant-based treatments.
